On Friday, Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) released topline results from the Phase 3 trial of the combined mRNA vaccine candidate against influenza and COVID-19 in healthy ...

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectivesThe trial did not meet one of its ...

FluMist is the only nasal flu vaccine, but it is not new. The FDA approved it in 2003 for people 5 to 49 years old before ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Vaccines for the Fall and Winter 2024–2025 season are now available. Generally, experts recommend COVID-19 and flu vaccines ...

The revamped vaccine is an effort by regulators and vaccine makers to keep pace with the virus, which continues to evolve ...

Discover the significant differences in influenza and COVID-19 vaccination rates among children receiving long-term ...

With all these shots, some Canadians may have questions about the benefit of each vaccine, whether they should get every shot and how often to get them, and if it's safe to get them all at once or if ...

“BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy ...